8-KOther EventsExhibits & Filings

BIOGEN INC. 8-K Report, Corporate Update (Jun 18, 2020)

Filed June 18, 2020For Securities:BIIB

Summary

Biogen Inc. (BIIB) announced on June 18, 2020, that the U.S. District Court for the Northern District of West Virginia ruled the asserted claims of its U.S. patent No. 8,399,514 invalid. This patent specifically covers the 480 mg/day daily dosing regimen of dimethyl fumarate for treating multiple sclerosis, which is the basis for its key drug, TECFIDERA®. This ruling is significant as it could impact the exclusivity and market protection of TECFIDERA®. Biogen has stated its intention to appeal this decision, indicating a commitment to defending its intellectual property. Investors should closely monitor the progress and outcome of this appeal, as it will have direct implications for TECFIDERA®'s future market position and Biogen's revenue streams.

Key Highlights

  • 1Biogen's U.S. patent No. 8,399,514, covering TECFIDERA®'s 480 mg/day dosing regimen for multiple sclerosis, has been found invalid by the U.S. District Court for the Northern District of West Virginia.
  • 2The ruling pertains to a specific patent related to the administration of dimethyl fumarate for treating MS.
  • 3Biogen intends to appeal the district court's decision.
  • 4This development could potentially impact the market exclusivity and competitive landscape for TECFIDERA®.
  • 5Investors should closely follow the appeal process.

Frequently Asked Questions

This patent covers the specific daily dosing regimen of 480 mg/day of dimethyl fumarate used to treat multiple sclerosis with the drug TECFIDERA®. A ruling of invalidity could weaken the market exclusivity and patent protection for TECFIDERA®.

Biogen has stated that it intends to appeal the decision. This indicates the company's commitment to defending its intellectual property rights related to TECFIDERA®.

If the appeal is unsuccessful, it could open the door for generic competition sooner than expected, potentially impacting TECFIDERA®'s sales and Biogen's revenue.

Investors should closely monitor the appeal process undertaken by Biogen and any subsequent rulings. The outcome of the appeal will be crucial in determining the future market exclusivity and competitive environment for TECFIDERA®.